Clinical Study on the Treatment of Stable Bronchiectasis With Bailing Capsules Combined With Guben Kechuan Granules

Prior treatment

• Previous respiratory diseases other than bronchiectasis (such as bronchial asthma, lung cancer, active pulmonary tuberculosis, interstitial lung disease, pulmonary thromboembolism and severe pneumonia, etc.);
• Inability to swallow the research drug;
• Participate in other clinical trials, use other research drugs or research devices within 30 days before randomization;
• Other traditional Chinese medicine treatments were used within 7 days before the use of the study drug and during the study period.

Other illness

• Bronchiectasis caused by cystic fibrosis, allergic bronchopulmonary aspergillosis, etc;
• Combined with serious diseases of the heart, liver, kidneys, digestive system, blood system, etc., evaluated by the researcher, including but not limited to acute severe hepatitis, liver failure, liver cirrhosis, acute renal failure, acute myocardial infarction, heart failure, gastric perforation, gastrointestinal bleeding, gastric cancer, intestinal cancer, acute leukemia, acute aplastic anemia, etc., subject to the judgment of the researcher;
• Known allergy to the test drug;
• In the past year, there has been a history of alcohol abuse, drug abuse or drug abuse;

Lab values

• Abnormal liver function was found in the patient screening examination, with the following criteria: total bilirubin \> 1.5×ULN; ALT \> 3×ULN; AST \> 3×ULN;

Age

• Women or men of childbearing age refused to use contraceptive measures during the study period;

Other

• Dry bronchiectasis mainly characterized by hemoptysis;
• Pregnant or lactating women;
• Any other factors that may not be suitable for participation in clinical research as determined by the researcher;

• 18-80 years old, gender not limited;
• It conforms to the Western medical diagnosis of bronchiectasis;
• There has been no acute exacerbation or respiratory tract infection in the past 4 weeks. (Acute exacerbation is defined as the deterioration of three or more of the following six conditions: cough, changes in sputum volume, purulent sputum, breathing difficulties or exercise tolerance, fatigue or discomfort, and hemoptysis, lasting for more than 48 hours, and considered by the clinician to require treatment);
• There have been at least two documented acute exacerbations in the past year, prescribed by doctors and diagnosed as signs and symptoms of respiratory tract infections;
• Pulmonary function tests can be conducted, and there is evidence of airflow limitation when screening vital capacity (FEV1/FVC ratio \<70%, and clinically stable at the time of entering the study);
• Voluntarily participate in this clinical trial and sign the informed consent form.